| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1471-4159.1996.66010047.X |
| P8608 | Fatcat ID | release_vq54waxrtbef3lomjax44rxr4m |
| P3181 | OpenCitations bibliographic resource ID | 2129414 |
| P698 | PubMed publication ID | 8522988 |
| P2093 | author name string | B L Roth | |
| D R Sibley | |||
| H Y Meltzer | |||
| J E Lachowicz | |||
| K Huebner | |||
| M A Metcalf | |||
| M W Hamblin | |||
| N Khan | |||
| R Kohen | |||
| T Druck | |||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | serotonin | Q167934 |
| histamine receptor activity | Q14865482 | ||
| 5-hydroxytryptamine receptor 6 | Q21109363 | ||
| P304 | page(s) | 47-56 | |
| P577 | publication date | 1996-01-01 | |
| P1433 | published in | Journal of Neurochemistry | Q6295643 |
| P1476 | title | Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor | |
| P478 | volume | 66 |
| Q36346938 | 5-HT(6) receptor agonists and antagonists enhance learning and memory in a conditioned emotion response paradigm by modulation of cholinergic and glutamatergic mechanisms |
| Q43862483 | 5-HT(6) receptor antagonism potentiates the behavioral and neurochemical effects of amphetamine but not cocaine |
| Q50298318 | 5-HT4, 6 and 7 receptors can bind serotonin |
| Q37809899 | 5-HT6 Medicinal Chemistry |
| Q37809902 | 5-HT6 Receptor Charactertization |
| Q50420988 | 5-HT6 receptor agonist and antagonist modulates ICV-STZ-induced memory impairment in rats. |
| Q28287100 | 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease |
| Q34138219 | 5-HT6 receptor binding sites in schizophrenia and following antipsychotic drug administration: autoradiographic studies with [125I]SB-258585. |
| Q27006820 | 5-HT6 receptors and Alzheimer's disease |
| Q33489581 | 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo |
| Q37780550 | 5-hydroxytryptamine subtype 6 receptor modulators: a patent survey |
| Q38027891 | 5HT(6) receptor antagonists: a patent update. Part 1. Sulfonyl derivatives |
| Q28184669 | 5‐HT6 receptor antagonist SB‐271046 enhances extracellular levels of monoamines in the rat medial prefrontal cortex |
| Q46848285 | A null mutation of the serotonin 6 receptor alters acute responses to ethanol |
| Q28142963 | A review of central 5-HT receptors and their function |
| Q38298172 | A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. |
| Q37872282 | Advances in the design of 5-HT6 receptor ligands with therapeutic potential |
| Q36756370 | Alterations of serotonin transmission in schizophrenia |
| Q35041190 | Alzheimer's disease and age-related memory decline (preclinical) |
| Q44092155 | An RT-PCR study of 5-HT(6) and 5-HT(7) receptor mRNAs in the hippocampal formation and prefrontal cortex in schizophrenia. |
| Q48149826 | Anxiogenic-like effects and reduced stereological counting of immunolabelled 5-hydroxytryptamine6 receptors in rat nucleus accumbens by antisense oligonucleotides |
| Q34751885 | Assignment of the human serotonin 4 receptor gene (HTR4) to the long arm of chromosome 5 (5q31-q33). |
| Q53232380 | Association analysis of the 5-HT6 receptor polymorphism C267T in Alzheimer's disease. |
| Q44635660 | Association of dopaminergic and serotonergic genes with tardive dyskinesia in patients with chronic schizophrenia |
| Q78223054 | Association study of serotonin-6 receptor variant (C267T) with schizophrenia and aggressive behavior |
| Q43981464 | Bicyclic piperazinylbenzenesulphonamides are potent and selective 5-HT6 receptor antagonists |
| Q34737074 | Binding of serotonin and N1-benzenesulfonyltryptamine-related analogs at human 5-HT6 serotonin receptors: receptor modeling studies |
| Q38337647 | Central distribution and function of 5-HT6 receptor subtype in the rat brain |
| Q35042511 | Characterization of SB-271046: a potent, selective and orally active 5-HT(6) receptor antagonist |
| Q24674871 | Characterization of [(125)I]-SB-258585 binding to human recombinant and native 5-HT(6) receptors in rat, pig and human brain tissue |
| Q48022648 | Characterization of desamino-5-[125I]iodo-3-methoxy-zacopride ([125I]MIZAC) binding to 5-HT3 receptors in the rat brain |
| Q73247327 | Characterization of radioactive metabolites of 5-HT2A receptor PET ligand [18F]altanserin in human and rodent |
| Q28646142 | Characterization of the 5-HT6 receptor coupled to Ca2+ signaling using an enabling chimeric G-protein |
| Q24675513 | Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats |
| Q47812592 | Cloning and functional expression of an Aplysia 5-HT receptor negatively coupled to adenylate cyclase. |
| Q28591225 | Cloning of the mouse 5-HT6 serotonin receptor and mutagenesis studies of the third cytoplasmic loop |
| Q35590479 | Combination of Pharmacophore Matching, 2D Similarity Search, and In Vitro Biological Assays in the Selection of Potential 5-HT6 Antagonists from Large Commercial Repositories |
| Q57039732 | Computer-Aided Studies for Novel Arylhydantoin 1,3,5-Triazine Derivatives as 5-HT₆ Serotonin Receptor Ligands with Antidepressive-Like, Anxiolytic and Antiobesity Action In Vivo |
| Q85369293 | Cyclopropyl-tryptamine analogues: synthesis and biological evaluation as 5-HT(6) receptor ligands |
| Q28540701 | Direct interaction and functional coupling between human 5-HT6 receptor and the light chain 1 subunit of the microtubule-associated protein 1B (MAP1B-LC1) |
| Q48691924 | Distribution of serotonin receptor of type 6 (5-HT₆) in human brain post-mortem. A pharmacology, autoradiography and immunohistochemistry study. |
| Q83753521 | Distribution, level, pharmacology, regulation, and signaling of 5-HT6 receptors in rats and marmosets with special reference to an experimental model of parkinsonism |
| Q86706640 | Dynamics and structural determinants of ligand recognition of the 5-HT6 receptor |
| Q34111024 | E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat. |
| Q41307502 | Effects of ST1936, a selective serotonin-6 agonist, on electrical activity of putative mesencephalic dopaminergic neurons in the rat brain |
| Q28565407 | Effects of clozapine and haloperidol on 5-HT6 receptor mRNA levels in rat brain |
| Q24675480 | Efficacy of selective 5-HT6 receptor ligands determined by monitoring 5-HT6 receptor-mediated cAMP signaling pathways |
| Q34650329 | Evidence for 5-HT2B and 5-HT7 receptor-mediated relaxation in pulmonary arteries of weaned pigs |
| Q51564207 | Extended N-Arylsulfonylindoles as 5-HT₆ Receptor Antagonists: Design, Synthesis & Biological Evaluation. |
| Q35680883 | From molecular biology to pharmacogenetics: a review of the literature on antidepressant treatment and suggestions of possible candidate genes |
| Q40981360 | Function and distribution of three rat 5-hydroxytryptamine7 (5-HT7) receptor isoforms produced by alternative splicing |
| Q28243874 | Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells |
| Q41622739 | Functional characteristics of heterologously expressed 5-HT receptors |
| Q44485883 | Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha 2C, 5-HT6, and 5-HT1A receptors |
| Q30439012 | Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia |
| Q35645744 | Idalopirdine as a treatment for Alzheimer's disease |
| Q82533971 | Identification of 3-sulfonylindazole derivatives as potent and selective 5-HT6 antagonists |
| Q35025708 | Identification of 5-hydroxytryptamine receptors positively coupled to adenylyl cyclase in rat cultured astrocytes. |
| Q52371420 | Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry. |
| Q40621795 | Identification of a Potent and Selective 5-HT6Antagonist: One-Step Synthesis of (E)-3-(Benzenesulfonyl)-2- (methylsulfanyl)pyrido[1,2-a]pyrimidin- 4-ylidenamine from 2-(Benzenesulfonyl)-3,3- bis(methylsulfanyl)acrylonitrile |
| Q48291852 | Identification of a human 5-HT6 receptor variant produced by alternative splicing |
| Q22001497 | Identification, characterization and mapping of the human ZIS (zinc-finger, splicing) gene |
| Q34847404 | Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht(6) receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task |
| Q38199670 | Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. |
| Q42020074 | Investigation of stretching behaviour induced by the selective 5-HT6 receptor antagonist, Ro 04-6790, in rats. |
| Q35229475 | Investigation of the structure requirement for 5-HT₆ binding affinity of arylsulfonyl derivatives: a computational study |
| Q35027086 | Involvement of 5-hydroxytryptamine7 receptors in inhibition of porcine myometrial contractility by 5-hydroxytryptamine |
| Q31861838 | Lack of association between the T-->C 267 serotonin 5-HT6 receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia |
| Q38683808 | Modulating 5-HT4 and 5-HT6 receptors in Alzheimer's disease treatment. |
| Q34584191 | Molecular genetics of schizophrenia: past, present and future |
| Q28206145 | Molecular, pharmacological and functional diversity of 5-HT receptors |
| Q28074736 | Monoaminergic Mechanisms in Epilepsy May Offer Innovative Therapeutic Opportunity for Monoaminergic Multi-Target Drugs |
| Q28210479 | Multiplicity of mechanisms of serotonin receptor signal transduction |
| Q51804785 | N-arylsulfonyl-2-vinyltryptamines as new 5-HT6 serotonin receptor ligands. |
| Q33923475 | N1-(Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists |
| Q40638545 | N1-benzenesulfonylgramine and N1-benzenesulfonylskatole: novel 5-HT6 receptor ligand templates |
| Q28236198 | Neuropharmacological profile of novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-208466 |
| Q48095780 | New arylpiperazinylalkyl derivatives of 8-alkoxy-purine-2,6-dione and dihydro[1,3]oxazolo[2,3-f]purinedione targeting the serotonin 5-HT1A /5-HT2A /5-HT7 and dopamine D2 receptors |
| Q47321232 | No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation |
| Q43720993 | Novel polymorphism in the 5'-upstream region of the human 5-HT6 receptor gene and schizophrenia |
| Q38205485 | Novel thiazole derivatives: a patent review (2008 - 2012. Part 2). |
| Q40728180 | Overexpression of 5-HT1B receptor in dorsal raphe nucleus using Herpes Simplex Virus gene transfer increases anxiety behavior after inescapable stress. |
| Q43760124 | Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. |
| Q37223396 | Peripheral serotonin-mediated system suppresses bone development and regeneration via serotonin 6 G-protein-coupled receptor |
| Q42926677 | Pharmacogenetic study of serotonin 6 receptor gene with antidepressant response in major depressive disorder in the Japanese population |
| Q34155796 | Pharmacogenetics of antidepressant response |
| Q35026088 | Pharmacogenetics of antidepressants |
| Q34117799 | Pharmacological profile of SB-357134: a potent, selective, brain penetrant, and orally active 5-HT(6) receptor antagonist |
| Q64238431 | Physical and Functional Interaction between 5-HT Receptor and Nova-1 |
| Q39737412 | Physical interaction of Jab1 with human serotonin 6 G-protein-coupled receptor and their possible roles in cell survival |
| Q43800989 | Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine |
| Q44557820 | Potential clozapine target sites on peripheral hematopoietic cells and stromal cells of the bone marrow |
| Q33706897 | Potential role of the 5-HT6 receptor in depression and anxiety: an overview of preclinical data |
| Q48479735 | Preclinical evaluation of [18F]2FNQ1P as the first fluorinated serotonin 5-HT6 radioligand for PET imaging. |
| Q24649687 | Predicting new molecular targets for known drugs |
| Q48200194 | Regulation of glial Na+/K+-ATPase by serotonin: identification of participating receptors |
| Q52313842 | Restoration of physiological expression of 5-HT6 into the primary cilia of null mutant neurons lengthens both primary cilia and dendrites. |
| Q34247123 | Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790. |
| Q34871885 | Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder |
| Q42537934 | Serotonergic basis of antipsychotic drug effects in schizophrenia. |
| Q39134334 | Serotonin 5-HT6 Receptor Antagonists in Alzheimer's Disease: Therapeutic Rationale and Current Development Status |
| Q36413592 | Serotonin 6 receptor controls Alzheimer's disease and depression |
| Q45776602 | Serotonin 6 receptor gene and schizophrenia: case-control study and meta-analysis |
| Q34143560 | Serotonin Receptors – From Molecular Biology to Clinical Applications |
| Q39013628 | Serotonin induces the migration of PC12 cells via the serotonin receptor 6/cAMP/ERK pathway |
| Q37132811 | Serotonin pharmacology in the gastrointestinal tract: a review |
| Q35810041 | Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders |
| Q40190491 | Stable expression of adenylyl cyclase 2 leads to the functional rescue of human 5-HT6 receptor in a CHODUKX cell line |
| Q40436775 | Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs |
| Q28611461 | Stimulation of type 1 and type 8 Ca2+/calmodulin-sensitive adenylyl cyclases by the Gs-coupled 5-hydroxytryptamine subtype 5-HT7A receptor |
| Q28275114 | Study of a mechanism responsible for potential antidepressant activity of EMD 386088, a 5-HT6 partial agonist in rats |
| Q48532821 | Synthesis and 5-HT-3 receptor binding of 2- and 3-(halo)alkoxyl substituted (S)-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chlorobenzamides as potential radioligands |
| Q48447583 | The 5-HT1A and 5-HT2A/2C receptor antagonists WAY-100635 and ritanserin do not attenuate D-fenfluramine-induced fos expression in the brain |
| Q34363831 | The chemical basis of pharmacology |
| Q46375972 | The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? |
| Q34663667 | The molecular biology of serotonin receptors: therapeutic implications for the interface of mood and psychosis |
| Q35757723 | The pharmacogenomics of selective serotonin reuptake inhibitors. |
| Q37830311 | The role of G protein-coupled receptors in the pathology of Alzheimer's disease |
| Q37826638 | The role of serotonin in the NMDA receptor antagonist models of psychosis and cognitive impairment |
| Q37987116 | The serotonin-6 receptor as a novel therapeutic target |
| Q42496714 | Whole spectrum analysis of ligand efficacy at constitutively active human wild-type and S267K 5-HT6 receptors in HEK-293F cells |
Search more.